Advertisement
Advertisement
BRVE
Braveheart Bio, Inc. Common Stock
18.60
USDSponsored
+1.19
+6.80%
Nov 06, 15:58 UTC -5
Closed
After-Market
18.58
-0.02
-0.11%
Braveheart Bio, Inc. Common Stock (BRVE) Earnings
BRVE Earnings Reports
Positive Surprise Ratio
BRVE beat 0 of 1 last estimates.
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Braveheart Bio, Inc. Common Stock earnings per share and revenue
On Sep 08, 2026, BRVE reported earnings of -2.50 USD per share (EPS) for Q2 26, missing the estimate of 4.39 USD, resulting in a -157.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.70% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Braveheart Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Braveheart Bio, Inc. Common Stock reported EPS of -$2.50, missing estimates by -157.05%, and revenue of $0.00, 0% as expectations.
How did the market react to Braveheart Bio, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -1.7%, changed from $29.41 before the earnings release to $28.91 the day after.
When is Braveheart Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Braveheart Bio, Inc. Common Stock's next earnings report?
Based on --
analysts, Braveheart Bio, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.